All articles tagged with #clpp
CWRU researchers link alpha-synuclein to mitochondrial dysfunction in Parkinsons by binding to the ClpP enzyme; they designed a CS2 decoy to block this interaction, reducing inflammation and restoring function in cells and animal models, offering a potential root-cause therapy with human trials possible in about five years.
Scientists show that alpha-synuclein directly binds the ClpP enzyme, sabotaging mitochondria and fueling neuron loss in Parkinson's models; they created CS2, a decoy that blocks this interaction, restoring mitochondrial function, reducing inflammation, and improving movement and cognition in tissue and animal models, with plans to advance toward human trials.
Researchers have identified that alpha-synuclein binds to the mitochondrial enzyme ClpP, impairing energy production and accelerating neuron loss in Parkinson’s disease. They developed CS2, a decoy therapy that blocks this interaction and restores mitochondrial function, showing reduced inflammation and improved movement and cognition in human tissue, patient-derived neurons, and mouse models. The work points to a disease-modifying treatment targeting a root cause, with plans to advance toward human trials in the next five years.